ArticleCureus2018
Epidemiology and Survival of Esophageal Cancer Patients in an American Cohort.
Article in Cureus, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials.World journal of surgical oncology · 2020Pooled it
- Correlates of the Stage of Esophageal Cancer at Diagnosis Among Patients: A Mixed-Methods Cross-Sectional Study.Cancer management and research · 2026Article
- Determinants of survival outcomes among esophageal cancer patients at a national referral hospital in Kenya.Chronic diseases and translational medicine · 2023Article
- Application of Amiodarone and Cedilan in the Treatment of Patients with Arrhythmia after Esophageal and Lung Cancer.Evidence-based complementary and alternative medicine : eCAM · 2023Article
- Clinicopathological characteristics and treatment outcomes of oesophageal cancer patients in Uganda.Ecancermedicalscience · 2023Article
- Unmet needs in Barret's esophagus diagnosis and treatment: a narrative review.Translational gastroenterology and hepatology · 2023Review
- Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancer.World journal of gastrointestinal oncology · 2022Article
- Effects of Ion-Transporting Proteins on the Digestive System Under Hypoxia.Frontiers in physiology · 2022Review
- Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) as a Neoadjuvant Chemotherapy for Non-metastatic Esophageal Cancer (nMEC).Clinical medicine & research · 2021Article
- Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine.International journal of molecular sciences · 2021Review
- Plasma Changes of Branched-Chain Amino Acid in Patients with Esophageal Cancer.Middle East journal of digestive diseases · 2021Article
- Endoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma: Rationale, Candidates, and Challenges.Gastrointestinal endoscopy clinics of North America · 2021Review
- DEK overexpression is predictive of poor prognosis in esophageal squamous cell carcinoma.Archives of medical science : AMS · 2021Article
- Surveillance of Esophageal Cancer in the Republic of Uzbekistan from 2000 to 2018.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Racial and ethnic disparities in mortality from gastric and esophageal adenocarcinoma.Cancer medicine · 2020Article
- Vacuolar HCells · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives This study seeks to delineate trends in esophageal cancer patients in an American cohort and, in particular, examine the impact of race and histology on survival. Methods The association between over 50 variables between histology and race subgroups was evaluated. Survival was calculated using Kaplan-Meier curves and a multivariable Cox regression analysis (MVA) was performed. Results Poorer survival was noted in black vs. white (193 ± 65 days vs. 254 ± 39, 95% CI 205-295, p=0.07) and squamous cell cancer (SCC) vs. adenocarcinoma (AC) (233 ± 24 days vs. 303 ± 48, 95% CI 197-339, p=0.01) patients. In patients with resectable cancer, blacks had poorer survival than whites (253 ± 46 days vs. 538 ± 202, 95% CI 269-603, p=0.03), and SCC had poorer survival than AC (333 ± 58 vs. 638 ± 152 days, 95% CI 306-634, p=0.006). A higher percentage of white patients received surgery compared to black patients (36% vs. 8%, p=0.08). MVA revealed that only surgery was an independent predictor of mortality (p=0.001). Conclusion Black race and SCC were associated with poorer survival. On MVA, surgery was an independent predictor of mortality. Clinicians should be aggressive in offering potentially curative procedures to patients and eliminating socioeconomic barriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.